• Share
  • Email
  • Embed
  • Like
  • Private Content
The FDA Guidance of Risk-Based Approach to Monitoring as viewed from CDM
 

The FDA Guidance of Risk-Based Approach to Monitoring as viewed from CDM

on

  • 2,644 views

- Interactions: Sponsors, Clinical Operations and CDM ...

- Interactions: Sponsors, Clinical Operations and CDM
- Risk-Based Monitoring
- Challenges for Sponsors
- Challenges for Monitors
- Challenges for CDM
- Implementation – Will there be any affect on data quality or integrity?
- Will the Risked-Based Approach require roles/skill set adjustments?

Statistics

Views

Total Views
2,644
Views on SlideShare
2,641
Embed Views
3

Actions

Likes
1
Downloads
31
Comments
0

1 Embed 3

http://www.linkedin.com 3

Accessibility

Categories

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    The FDA Guidance of Risk-Based Approach to Monitoring as viewed from CDM The FDA Guidance of Risk-Based Approach to Monitoring as viewed from CDM Presentation Transcript

    • The FDA Guidance of Risk-BasedApproach to Monitoring as Viewed From CDM Presented By William Gluck, PhD VP, DATATRAK Clinical and Consulting Services DATATRAK International, Inc. For
    • AgendaInteractions: Sponsors, Clinical Operations and CDMRisk-Based Monitoring – Challenges for Sponsors – Challenges for Monitors – Challenges for CDMImplementation – Will there be any affect on data quality or integrity?Will the Risked-Based Approach require roles/skill set adjustments?
    • Traditional Paper-Based Work-FlowPatientData Database
    • Risked-Based Monitoring Work-Flow CentralizedSites Database CRA CDM
    • Supporting Risked-Based Monitoring – Challenges for Sponsors• “The most important tool for ensuring human subject protection and high-quality data is a well- designed and articulated protocol.”• Guidance intends to assist sponsors in developing risk-based monitoring strategies and plans – Tailored to the specific human subject protection and data integrity risks of the trial – Focuses on critical study parameters – Encourages use of a combination of monitoring activities – Encourages greater reliance on centralized monitoring practices, where appropriate – it is OK not to do 100% SDV
    • Supporting Risked-Based Monitoring – Challenges in Clinical Operations• Trial specific• Describe monitoring methods, responsibilities, and requirements• Components to consider – Description of monitoring approaches (e.g., timing, intensity, activities, documentation) – Targeted SDV – Communication of monitoring results – Management of noncompliance – Training and study-specific information – Monitoring plan amendments
    • Supporting Risked-Based Monitoring – Challenges in CDM• Centralized Monitoring• Quality and Integrity Checks – Increased checks – Increased data collection• Technologically Few Challenges• Process/Workflow Flow – KEY!
    • Data Quality/Integrity• Identify critical study data and processes, e.g. – Endpoints – Serious Adverse Events – Randomization/ Blinding – Consent – Eligibility Criteria – Risks specific to protocol design and conduct• Perform and document a risk assessment to identify risks to these critical data and processes• Design plans tailored to address important and likely risks identified during risk assessment
    • Role or Skill Set Adjustments Needed to Support Risked-Based Monitoring• Sponsors• Site Coordinators/Staff• CRAs/Monitors – Increases in support and technology skills• CDM – Increases in technology process – Increases in training skills
    • Summary• From the perspective of CDM – Need coordination in planning across functional groups/departments – No overwhelming hurdles to implementation• Guidance reflects acknowledgment that changes to the clinical trial enterprise are OK• Process integration is key to efficient use of resources and to add quality
    • William Gluck, Ph.D.VP, DATATRAK Clinical and Consulting Services Datatrak International, Inc. Phone: 919-651-0222 Cell: 919-522-9681 E-Mail: Bill.Gluck@datatrak.net